Retrieve all available abstracts of the following 196 articles: HTML format
Single Articles
YANG L, Zhang Z, Xu M, Shang M, et al Constructing a prognostic model based on MPT-related genes and investigate the
characteristics of immune infiltration in bladder cancer.
Discov Oncol. 2025;16:460. PubMed Abstract available
VAN GENNEP EJ, Pisano G, KleinJan GH, Rietbergen DDD, et al Prospective clinical study of sentinel node detection in bladder cancer using a
hybrid tracer - Towards replacement of pelvic lymph node dissection in cases with
sentinel node visualization on SPECT/CT?
Eur J Nucl Med Mol Imaging. 2025 Apr 4. doi: 10.1007/s00259-025-07240. PubMed Abstract available
ARTILES MEDINA A, Subiela JD, Tagalos Munoz A, Tato Diez M, et al Clinical outcomes of BCG infections in patients undergoing intravesical
immunotherapy for non-muscle-invasive bladder cancer: a systematic review and
meta-analysis.
Minerva Urol Nephrol. 2025;77:13-24. PubMed Abstract available
SONG J, Qiao J, Chen M, Li J, et al Chaetoglobosin A induces apoptosis in T-24 human bladder cancer cells through
oxidative stress and MAPK/PI3K-AKT-mTOR pathway.
PeerJ. 2025;13:e19085. PubMed Abstract available
AL-QUDIMAT AR, Sabir D, Elamin M, Ching M, et al Implementing VIRADS score for image-guided assessment of muscle invasiveness in
bladder cancer pre-TURBT: An updated meta-analysis.
Arab J Urol. 2024;23:97-108. PubMed Abstract available
LIM KY, Huynh TNA, Wei G, Kuriakose J, et al Intravesical gemcitabine and docetaxel vs. re-induction Bacillus Calmette Guerin
as first-line salvage therapy for non-muscle invasive bladder cancer.
BJUI Compass. 2025;6:e70012. PubMed Abstract available
LU X, Shui KM, Ji H, Chen JY, et al Nerve infiltration of bladder cancer predicts response to immunotherapy.
Biochem Biophys Res Commun. 2025;761:151687. PubMed Abstract available
XIONG K, Chen S, Xu H, Tu S, et al RNF112 Facilitates Ubiquitin-Mediated Degradation of c-Myc, Suppressing
Proliferation, Migration and Lipid Synthesis in Bladder Cancer.
Adv Sci (Weinh). 2025 Apr 3:e2408311. doi: 10.1002/advs.202408311. PubMed Abstract available
LIU J, Zhou W, Zhang W, Chang C, et al The safety and efficacy of BCG combined with mitomycin C compared with BCG
monotherapy in patients with non-muscle-invasive bladder cancer: A systematic
review and meta-analysis.
Open Med (Wars). 2025;20:20241134. PubMed Abstract available
DI SPIRITO A, Balkhi S, Vivona V, Mortara L, et al Key immune cells and their crosstalk in the tumor microenvironment of bladder
cancer: insights for innovative therapies.
Explor Target Antitumor Ther. 2025;6:1002304. PubMed Abstract available
REZAEENIYA F, Hasandoost F, Abedi AR, Amanollahi A, et al Effectiveness of the Continuous Care Model on Quality of Life, Sexual
Satisfaction and Function in Bladder Cancer Patients Undergoing Tumor Resection
Surgery: A Randomized Control Trial.
Clin Genitourin Cancer. 2025 Mar 4:102321. doi: 10.1016/j.clgc.2025.102321. PubMed Abstract available
HE Y, Chen Y, Gao C A mendelian randomization study on the association between type 2 diabetes and
the risk of bladder cancer.
Discov Oncol. 2025;16:446. PubMed Abstract available
PAUDYAL P, Mete U, Gorsi U, Kumar S, et al Usefulness of multiparametric MRI for local staging of bladder cancer.
Urologia. 2025;92:231-236. PubMed Abstract available
LU BS, Liu KL, Yin YW, Zhang YP, et al A novel feedback regulation loop of METTL11A-MAFG-NPL4 promotes bladder cancer
cell proliferation and tumor progression.
FASEB J. 2025;39:e70466. PubMed Abstract available
Correction to "Loss of Polarity Protein Par3, via Transcription Factor Snail,
Promotes Bladder Cancer Metastasis".
Cancer Sci. 2025 Apr 1. doi: 10.1111/cas.70073. PubMed
LAKKIS NA, Osman MH, Abdallah RM, Mokalled NM, et al Bladder Cancer in Lebanon: An Updated Epidemiological Comparison with Global
Regions and a Comprehensive Review of Risk Factors.
Cancer Control. 2025;32:10732748251330696. PubMed Abstract available
IBRAHIM TS, Saraya MS, Saleh AI, Rabie AH, et al An efficient graph attention framework enhances bladder cancer prediction.
Sci Rep. 2025;15:11127. PubMed Abstract available
PENG D, Yang W, Tang T, He A, et al PLA2G7 promotes immune evasion of bladder cancer through the JAK-STAT-PDL1 axis.
Cell Death Dis. 2025;16:234. PubMed Abstract available
ERAKY A, Kolanukuduru KP, Hug B, Ben-David R, et al Differential response of low- and high-grade intermediate-risk
non-muscle-invasive bladder cancer to bacillus Calmette-Guerin and
gemcitabine-docetaxel therapy.
Urol Oncol. 2025 Mar 31:S1078-1439(25)00105. PubMed Abstract available
ISMAIL A, Kotb A Advocating female genital-sparing cystectomy as the standard of care for women
with bladder cancer Re: "2025 Canadian Urological Association Guideline:
Muscle-invasive bladder cancer" (Can Urol Assoc J 2025;19:E1-16).
Can Urol Assoc J. 2025;19:E138-E139. PubMed
NEGRIER S, Bonastre J, Colrat F, Teitsson S, et al Cost-effectiveness of nivolumab compared with surveillance for adjuvant treatment
of muscle-invasive urothelial carcinoma at high risk of recurrence in France.
World J Urol. 2025;43:202. PubMed Abstract available
LI J, Chong TW, Fong KY, Han BLJ, et al Will artificial intelligence (AI) replace cytopathologists: a scoping review of
current applications and evidence of A.I. in urine cytology.
World J Urol. 2025;43:200. PubMed Abstract available
SZELES A, Kubik A, Vancsa S, Grunwald V, et al Prognostic and predictive value of pre-treatment blood-based inflammatory
biomarkers in patients with urothelial carcinoma treated with immune checkpoint
inhibitors: a systematic review and meta-analysis.
Front Immunol. 2025;16:1554048. PubMed Abstract available
TORNIAI M, Martino GP, Gucciardino C, Angelici S, et al Case Report: Pembrolizumab in a patient with preexisting paraneoplastic
dermatomyositis and sarcomatoid urothelial carcinoma. Searching for balance.
Front Immunol. 2025;16:1558964. PubMed Abstract available
TABAEI S, Zareinejad M, Haghshenas MR, Shakhssalim N, et al Investigation of new autoantibodies in urothelial bladder cancer for biomarker
discovery using immunoproteomics.
Discov Oncol. 2025;16:436. PubMed Abstract available
HUANG Y, Li Z, Qiu H, Shen C, et al Drug-Loaded Mitochondrial Targeted Nanoparticles for Tumor Imaging and PDT/PTT
Combined Chemotherapy in Muscle-Invasive Bladder Cancer.
Macromol Biosci. 2025 Mar 31:e2400575. doi: 10.1002/mabi.202400575. PubMed Abstract available
QI K, Cheng H, Jiang Y, Zheng Y, et al Contribution of smoking to the global burden of bladder cancer from 1990 to 2021
and projections to 2046.
Tob Induc Dis. 2025;23:10. PubMed Abstract available
AFFERI L, Jahn B, Kelkar AH, Dijk SW, et al Perioperative cisplatin-based chemotherapy for muscle-invasive bladder cancer: a
decision analysis.
World J Urol. 2025;43:197. PubMed Abstract available
QIU Y, Wang Y, Liu J, Liu B, et al Single-cell sequencing uncovers a high ESM1-expression endothelial cell
subpopulation associated with bladder cancer progression and the
immunosuppressive microenvironment.
Sci Rep. 2025;15:10946. PubMed Abstract available
LI K, Li Y, Zhang Y, Lv J, et al N6-methyladenosine-modified RNF220 induces cisplatin resistance and immune escape
via regulating PDE10A K48-linked ubiquitination in bladder cancer.
Biochem Pharmacol. 2025;236:116903. PubMed Abstract available
RAMADHAN HH, Abdul-Rasheed OF, Alhamedi SAM, Mezban SG, et al Exploring The Prevalence of Telomerase Reverse Transcriptase Promoter Mutations
in Bladder Cancer Patients and Their Correlation with Tumor Characteristics.
Asian Pac J Cancer Prev. 2025;26:1053-1058. PubMed Abstract available
EL-ZOHERY NT, Shalaby YR, Kasem AI, Mostafa RR, et al CD 14 Expression in Urothelial Carcinoma of The Urinary Bladder
(Histopathological and Immunohistochemical Study).
Asian Pac J Cancer Prev. 2025;26:889-897. PubMed Abstract available
MANGOLD MH, Nientiedt M, Waldbillig F, Michel MS, et al Optimizing treatment selection: outcomes of radical cystectomy in patients
eligible for trimodal therapy.
World J Urol. 2025;43:196. PubMed Abstract available
DONG S, Wang L, Liu X, Hou D, et al CELF2 inhibits bladder cancer progression by decreasing the stability of CXCL5.
Life Sci. 2025;370:123585. PubMed Abstract available
KARUNAMURTHY A, Davar D There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint
Blockade in Urothelial Carcinoma.
Cancer Immunol Res. 2025;13:454-455. PubMed Abstract available
PARK S, Kang H, Choi Y, Yoon SG, et al Precision screening with sequential multi-algorithm reclassification technique
(SMART): Saving bladders from unnecessary cystectomy.
Comput Biol Med. 2025;189:109980. PubMed Abstract available
MILLER EJ, Galsky MD An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of
advanced urothelial carcinoma.
Expert Rev Anticancer Ther. 2025;25:319-326. PubMed Abstract available
MARTINEZ LM, Ribeiro LCSL, Guidi RG, de Moraes CMT, et al Cell-free Tumor DNA: a Promising Technology for Diagnosis, Surveillance and
Therapeutic Decision in Urothelial Carcinoma of the Bladder.
Curr Oncol Rep. 2025;27:225-235. PubMed Abstract available
GALSKY MD, Kockx M, Roels J, Van Elzen R, et al Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in
Urothelial Cancer.
Cancer Immunol Res. 2025;13:476-486. PubMed Abstract available
ZHANG Z, Liu CW, Donaghue JD, Murray EJ, et al Patient-specific adaptive planning margin for whole bladder radiation therapy.
J Appl Clin Med Phys. 2025;26:e14617. PubMed Abstract available
BIZZARRI FP, Campetella M, Russo P, Marino F, et al Risk factors for benign uretero-enteric anastomotic strictures after open radical
cystectomy and ileal conduit.
Urologia. 2025;92:224-230. PubMed Abstract available
CLAUSER S, Palermo M, Palermo S, Comploj E, et al [An extremely rare case of multiple recurrences of urothelial carcinoma in an
ileal neobladder: a case report and review of the literature].
Aktuelle Urol. 2025;56:164-169. PubMed Abstract available
FERNANDES G, Khumanthem G, Harinkhede N, Rojekar A, et al Primary signet ring cell adenocarcinoma arising in exstrophy of the urinary
bladder (epispadias-exstrophy complex).
Indian J Pathol Microbiol. 2025;68:165-167. PubMed Abstract available
XING Z, Yang T, Li X, Xu H, et al High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder
cancer to enfortumab vedotin therapy.
Cell Rep. 2025;44:115545. PubMed Abstract available
ZHUANG J, Wang Y, Wu X, Peng Z, et al SIGMAR1 screened by a GPCR-related classifier regulates endoplasmic reticulum
stress in bladder cancer.
J Transl Med. 2025;23:417. PubMed Abstract available
JAIME-CASAS S, Chawla NS, Salgia NJ, Mercier B, et al Comparative Genomic Characterization of Small Cell Carcinoma of the Bladder
Compared With Urothelial Carcinoma and Small Cell Lung Carcinoma.
JCO Precis Oncol. 2025;9:e2400947. PubMed Abstract available
PATERSON C, Nguyen J, Fraser G, Pranavan G, et al Effect of Prehabilitation Interventions in People Affected by Bladder Cancer on
Long-Term Physical, Clinical, and Patient-Reported Outcome Measures: A Systematic
Review.
JCO Oncol Pract. 2025 Apr 10:OP2400984. doi: 10.1200/OP-24-00984. PubMed Abstract available
JOFFE BI, Christin JR, Le Coz C, Pingle SR, et al Management of Patients with Muscle-Invasive Bladder Cancer Achieving A Clinical
Complete Response after Neoadjuvant Therapy: Evidence and Consideration for
Active Surveillance.
Curr Urol Rep. 2025;26:36. PubMed Abstract available
XIE J, Mao QY, Chen JH, Shi HJ, et al Efficacy and safety of atezolizumab in the treatment of urothelial carcinoma: a
systematic review and meta-analysis.
World J Surg Oncol. 2025;23:133. PubMed Abstract available
HUANG Z, Huang S, Wu E, He Q, et al Comparison of hyperthermic intravesical chemotherapy using pirarubicin and
Bacillus Calmette-Guerin in the treatment of patients with high-risk
non-muscle-invasive bladder carcinoma: a retrospective study.
BMC Urol. 2025;25:81. PubMed Abstract available
SONG H, Xie G, Li Y, Hu X, et al A single-cell atlas of bladder cancer unveils dynamic cellular composition and
endothelial functional shifts during progression.
Discov Oncol. 2025;16:500. PubMed Abstract available
CAO W, Tan X, Li X, Wang Y, et al MIS18BP1 promotes bladder cancer cell proliferation and growth via inactivating
P53 signaling pathway.
Med Oncol. 2025;42:156. PubMed Abstract available
KHAZEM F, Zetoune AB Investigating the role of HMGA2 plasma level as a diagnostic marker in bladder
urothelial carcinoma patients.
J Cancer Res Clin Oncol. 2025;151:134. PubMed Abstract available
LONGONI M, Scilipoti P, Soria F, Pradere B, et al Oncological Outcomes in Bacillus Calmette-Guerin-naive High-risk
Non-muscle-invasive Bladder Cancer Patients: A Systematic Review on Current
Treatment Strategies and Future Perspectives.
Eur Urol Oncol. 2025 Apr 8:S2588-9311(25)00081-1. doi: 10.1016/j.euo.2025. PubMed Abstract available
ZHU RL, Kaufmann JD, Phan MD, Patel S, et al Paradoxical Emergence of Cutaneous Squamous Cell Carcinoma During Pembrolizumab
Treatment for Non-muscle Invasive Bladder Cancer and Subsequent Successful
Therapeutic Adjustments.
Cureus. 2025;17:e80293. PubMed Abstract available
LEE H, Jang H, Kim J, Maeng S, et al Bladder Cancer Medication Bacillus Calmette-Guerin-Cell Wall Skeleton Focusing on
Alternatives and Developments to Limitations.
J Cancer Prev. 2025;30:1-6. PubMed Abstract available
ZHANG YX, Albers R, Chen YT, Steineck G, et al The Association between Tea Consumption and Bladder Cancer Risk Based on the
Bladder Cancer Epidemiology and Nutritional Determinants (BLEND) International
Consortium.
Nutr Cancer. 2025 Apr 8:1-12. doi: 10.1080/01635581.2025.2488063. PubMed Abstract available
NHUNGO CJ, Nyongole OV, Mkony CA Radical cystectomy for bladder cancer in Sub-Saharan Africa: techniques,
challenges, and survival outcomes: a comprehensive review.
BMC Surg. 2025;25:143. PubMed Abstract available
MACCHI A, Bruniera M, Nazzani S, Ceccato T, et al mRNA-Based Urine Test Performance in High and Very-High Risk Non-Muscle-Invasive
Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL:
Vesical Tumor Early Monitoring: mRNA-Based Follow-up).
Clin Genitourin Cancer. 2025;23:102333. PubMed Abstract available
ZUBKOFF L, Ould Ismail AA, Jensen L, Haggstrom DA, et al Integration and evaluation of implementation strategies to improve
guideline-concordant bladder cancer surveillance: a prospective observational
study.
Implement Sci Commun. 2025;6:37. PubMed Abstract available
SINGH A, Raja D, Kaushal S, Seth A, et al Phenotypic characterization of tumor associated macrophages and circulating
monocytes in patients with Urothelial carcinoma of bladder.
Immunol Res. 2025;73:66. PubMed Abstract available
ARNOLD PJ, Spio M, Youssef R, Dehner C, et al Perivascular epithelioid cell neoplasm of the bladder with peritoneal metastasis.
Can J Urol. 2025;32:47-53. PubMed Abstract available
KONETY BR, Lotan Y, Myers A Safety of nadofaragene firadenovec-vncg: review of data from phase 2 and phase 3
studies.
Can J Urol. 2025;32:29-36. PubMed Abstract available
SUN S, Liu P, Xie G, Zheng J, et al CB-5083 and luteolin synergistically induce the apoptosis of bladder cancer cells
via multiple mechanisms.
Toxicol Appl Pharmacol. 2025 Apr 5:117333. doi: 10.1016/j.taap.2025.117333. PubMed Abstract available
YU D, Liu D, Liu Y Evaluating the Efficacy and Safety of Durvalumab Plus Radiotherapy in Second-Line
Treatment for Advanced Bladder Cancer.
Arch Esp Urol. 2025;78:248-254. PubMed Abstract available
Retraction: Puerarin inhibits proliferation and induces apoptosis by upregulation
of miR-16 in bladder cancer cell line T24.
Oncol Res. 2025;33:993. PubMed Abstract available
MAFFEZZOLI M, Giudice GC, Iovane G, Manini M, et al The effect of concomitant drugs on oncological outcomes in patients treated with
immunotherapy for metastatic urothelial carcinoma: a narrative review.
Oncol Res. 2025;33:741-757. PubMed Abstract available
ZHOU Y, Wang R, Zeng M, Liu S, et al Circulating tumor DNA: a revolutionary approach for early detection and
personalized treatment of bladder cancer.
Front Pharmacol. 2025;16:1551219. PubMed Abstract available
YIP AT, Bhat S A Rare Case of Bladder Cancer With Squamous Differentiation Causing Hypercalcemia
and Leukocytosis.
Cureus. 2025;17:e80111. PubMed Abstract available
YAMAMOTO T, Miyoshi H, Mima S, Kamata H, et al Effect of a hydrogel-based scaffold material on the establishment of a
patient-derived bladder cancer xenograft model.
J Toxicol Pathol. 2025;38:139-145. PubMed Abstract available
REMMELINK MJ, Peterson DJ, Nieuwenhuijzen JA, van Leeuwen TG, et al Perspective on the use of optics in bladder cancer detection and diagnosis.
J Biomed Opt. 2025;30:040601. PubMed Abstract available
TANAKA H, Fujii Y [Bladder Preservation Therapy for Bladder Cancer].
Gan To Kagaku Ryoho. 2025;52:217-223. PubMed Abstract available
DENG Q, Li S, Zhang Y, Jia Y, et al Development and validation of interpretable machine learning models to predict
distant metastasis and prognosis of muscle-invasive bladder cancer patients.
Sci Rep. 2025;15:11795. PubMed Abstract available
ZHANG P, Liu M, Zhang S, Lu C, et al Cytokeratin 17 activates AKT signaling to induce epithelial-mesenchymal
transition and promote bladder cancer progression.
BMC Urol. 2025;25:77. PubMed Abstract available
FENG Y, Wang J, Zhou A, Wu H, et al Short-term outcomes comparison of KangDuo 2.0 and Da Vinci Xi in radical
cystectomy.
Sci Rep. 2025;15:11739. PubMed Abstract available
BREA-IGLESIAS J, Gallardo-Gomez M, Oitaben A, Lazaro-Quintela ME, et al Genomics guiding personalized first-line immunotherapy response in lung and
bladder tumors.
J Transl Med. 2025;23:404. PubMed Abstract available
SHI ZD, Liu Y, Tao ZQ, Chao L, et al Apigenin inhibits recurrent bladder cancer progression by targeting VEGF-beta.
Cancer Lett. 2025;620:217676. PubMed Abstract available
YANG K, Chen Q, Chen J, Geng LF, et al Copper(II) Complexes of Pyrazolopyrimidine Derivatives as Anticancer Agents with
Enhanced Chemodynamic Therapy through Bimodal Apoptosis and Ferroptosis.
J Med Chem. 2025;68:7137-7152. PubMed Abstract available
SIMON N, Chandran E, Atiq S, Kydd AR, et al A phase II study of lurbinectedin with or without avelumab in small cell
carcinoma of the bladder (laser)-design and rationale.
Future Oncol. 2025;21:1171-1177. PubMed Abstract available
NOLL D, Milton T, Vather R, Cho J, et al Urological complications following pelvic exenteration are comparable to those
following radical cystectomy.
ANZ J Surg. 2025;95:761-765. PubMed Abstract available
KONG L, Weng B, Cai Q, Ma L, et al Evaluating Neoadjuvant Immunochemotherapeutic Response for Bladder Carcinoma
Using Amide Proton Transfer-Weighted MRI.
Acad Radiol. 2025;32:2090-2098. PubMed Abstract available
GUO H, Malone KE, Heckbert SR, Li CI, et al Statin use after cancer diagnosis and survival among patients with cancer.
Cancer Causes Control. 2025;36:443-455. PubMed Abstract available
Neutrophil senescence drives sexual dimorphism in bladder cancer.
Nat Immunol. 2025 Apr 18. doi: 10.1038/s41590-025-02133. PubMed
PANNHAUSEN J, Wirtz J, Mantwill K, Holm PS, et al Oncolytic virotherapy provides a potent therapy option for squamous bladder
cancer.
Sci Rep. 2025;15:13443. PubMed Abstract available
BIZZARRI FP, Nelson AW, Colquhoun AJ, Lobo N, et al Utility of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in
Detecting Lymph Node Involvement in Comparison to Conventional Imaging in
Patients with Bladder Cancer with Variant Histology.
Eur Urol Oncol. 2025 Apr 17:S2588-9311(25)00097. PubMed
LUO X, Luo Y Machine learning developed immune-related exosome signature for prognosis and
immunotherapy benefit in bladder cancer.
Discov Oncol. 2025;16:557. PubMed Abstract available
TANG M, Mahri S, Shiau YP, Mukarrama T, et al Multifunctional and Scalable Nanoparticles for Bimodal Image-Guided Phototherapy
in Bladder Cancer Treatment.
Nanomicro Lett. 2025;17:222. PubMed Abstract available
PERRON R, Iorio-Morin C, Chytka T, Simonova G, et al International multicenter study of stereotactic radiosurgery for bladder cancer
brain metastases.
J Neurooncol. 2025 Apr 18. doi: 10.1007/s11060-025-05039. PubMed Abstract available
KARACA Y, Kayipmaz S, Telci D, Akca O, et al Increased expression of transglutaminase-2 is associated with invasive disease in
bladder cancer.
Arch Ital Urol Androl. 2025 Apr 16:13615. doi: 10.4081/aiua.2025.13615. PubMed Abstract available
PENG Y, Song Y, Qin C, Ding M, et al Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy
decision-making for patients exposed to aristolochic acid.
Mol Med. 2025;31:140. PubMed Abstract available
LIN Z, Liang F, Hong G, Jiang X, et al TACC3 enhances glycolysis in bladder cancer cells through inducing acetylation of
c-Myc.
Cell Death Dis. 2025;16:311. PubMed Abstract available
CHEN R, Ding S, Fu X, Liu G, et al Intravesical chemotherapy enhances anti-tumor immunity in bladder cancer by
modulating CD8(+) T cell activation and Treg populations.
Biochem Biophys Res Commun. 2025;764:151782. PubMed Abstract available
ZULFIQQAR A, Liliana B, Mataho NL, Subekti E, et al The Use of Circulating Tumor Cells in T1 Stage Non-muscle Invasive Bladder
Cancer: A Systematic Review and Meta-Analysis.
Urol Res Pract. 2025;50:343-350. PubMed Abstract available
SAHA S, Gerdtham UG, Sjodahl G, Haggstrom C, et al Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant
chemotherapy in patients with muscle-invasive bladder cancer in a Swedish
setting.
Front Oncol. 2025;15:1556881. PubMed Abstract available
YOUSAF H, Javed A, Sultana N, Farouk K, et al Unlocking the secrets: Exploring the connection between HPV and bladder cancer in
Pakistan.
Urol Oncol. 2025 Apr 15:S1078-1439(25)00118. PubMed Abstract available
MASSON-LECOMTE A, Grisay G, Damme JV, Achard V, et al Challenges in Defining Clinical Complete Response to Systemic Therapy in
Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project.
Eur Urol Oncol. 2025 Apr 15:S2588-9311(25)00080. PubMed Abstract available
LI G, Zheng W, Zhang X, Chen Y, et al Dietary Fatty Acids and Bladder Cancer Risk: Insights from the PLCO Cancer
Screening Trial.
Nutr Cancer. 2025 Apr 16:1-11. doi: 10.1080/01635581.2025.2492138. PubMed Abstract available
JAIME-CASAS S, Imam A, Lama DJ, Okunowo O, et al Perioperative outcomes using template mapping after radical cystectomy and
extended lymph node dissection.
BMC Urol. 2025;25:91. PubMed Abstract available
LINDSKROG SV, Strandgaard T, Nordentoft I, Galsky MD, et al Circulating tumour DNA and circulating tumour cells in bladder cancer - from
discovery to clinical implementation.
Nat Rev Urol. 2025 Apr 15. doi: 10.1038/s41585-025-01023. PubMed Abstract available
EL-ATIER RA, Saraya MS, Saleh AI, Rabie AH, et al Accurate bladder cancer diagnosis using ensemble deep leaning.
Sci Rep. 2025;15:12880. PubMed Abstract available
KURET T, Kreft ME, Veranic P, Cemazar M, et al Phases of tight junction barrier disruption during transurothelial migration of
invasive urothelial cancer cells.
Sci Rep. 2025;15:12975. PubMed Abstract available
TONG Y, Chen Z, Wu J, Huang Q, et al METTL3 promotes an immunosuppressive microenvironment in bladder cancer via
m6A-dependent CXCL5/CCL5 regulation.
J Immunother Cancer. 2025;13:e011108. PubMed Abstract available
CHANG NW, Huang YH, Chen SL Rare complications of bladder perforation following the transurethral resection
of a bladder tumour with the immediate intravesical instillation of mitomycin C.
BMJ Case Rep. 2025;18:e265360. PubMed Abstract available
LI Z, Wang J, Wang W, Geng B, et al Integrated network pharmacology and RNA sequencing analysis to reveal the
mechanisms of Qici Sanling decoction in the treatment of gemcitabine resistant
bladder cancer.
J Pharm Biomed Anal. 2025;262:116885. PubMed Abstract available
VARGA L, Galdi A, Szegedi D, Herein A, et al Reduction of the planning target volume with daily online adaptive radiotherapy
in bladder cancer.
Strahlenther Onkol. 2025 Apr 15. doi: 10.1007/s00066-025-02397. PubMed Abstract available
YU R, Qin QJ, Haines GK, Oh WK, et al Intravesical BCG therapy-induced granulomatous prostatitis in a patient with
non-muscle invasive bladder cancer and prostate adenocarcinoma.
Urol Case Rep. 2025;60:103020. PubMed Abstract available
WANG G, Wang LL, Deng DD, Xu HX, et al Spectral CT findings of bladder urothelial carcinoma with gastric metastasis: a
case report.
BMC Urol. 2025;25:90. PubMed Abstract available
SURBER J, Semmler M, Enderlin D, Affentranger A, et al Microbiome landscapes of the bladder, intestine, and vagina in bladder cancer: a
systematic review.
Discov Oncol. 2025;16:525. PubMed Abstract available
ROUSSEAU C, Baumgartner P, Heymann MF, Taupin M, et al Preclinical and Clinical Feasibility Studies as the First Step Before Forthcoming
Intravesical Instillation of [(211)At]At-anti-CA-IX Antibody (ATO-101) Study in
Patients with Non-Muscle-Invasive Bladder Cancer Unresponsive to Standard of
Care.
Cancers (Basel). 2025;17:1190. PubMed Abstract available
RAJPUROHIT M, Golzy M, Chen NW, Murray KS, et al Relationship Among Body Mass Index, Survival, Cancer Treatment and Health-Related
Quality of Life Among Older Patients with Bladder Cancer.
Cancers (Basel). 2025;17:1200. PubMed Abstract available
BURNS CP, Parker JM, Schaap DM, Wakefield MR, et al From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment
of Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2025;17:1135. PubMed Abstract available
THORSTEINSSON K, Brandt SB, Jensen JB Patients with Metastatic or Locally Advanced Bladder Cancer Not Undergoing
Systemic Oncological Treatment-Characteristics and Long-Term Outcome in a
Single-Center Danish Cohort.
Cancers (Basel). 2025;17:1105. PubMed Abstract available
PARK C, Choi EO, Hwangbo H, Lee H, et al Erratum: Induction of apoptotic cell death in human bladder cancer cells by
ethanol extract of Zanthoxylum schinifolium leaf, through ROS-dependent
inactivation of the PI3K/Akt signaling pathway.
Nutr Res Pract. 2025;19:328-330. PubMed Abstract available
LIU Y, Hu J, Liao B, Zhu Z, et al DLEU2 facilitates bladder cancer progression through miR-103a-2-5p/SOS1 axis.
PeerJ. 2025;13:e18995. PubMed Abstract available
LIU JH, Du YZ, Liu F, Yang L, et al Potential therapeutic targets for bladder cancer: a proteome-wide Mendelian
randomization study.
Am J Cancer Res. 2025;15:1096-1108. PubMed Abstract available
NAKANE K, Okamoto A, Kato H, Hoshino H, et al Significance of split-dose cisplatin-based neoadjuvant chemotherapy followed by
robotic-assisted radical cystectomy for muscle invasive bladder cancer.
Transl Androl Urol. 2025;14:589-601. PubMed Abstract available
VUKOVIC MMN, Terzic ZS, Golubovic MM, Bojic MD, et al Bladder Cancer Mortality Trend in Montenegro: 1990-2021.
Iran J Public Health. 2025;54:414-423. PubMed Abstract available
LI G, Xia K Enhanced prognostic prediction of cancer-specific mortality in elderly bladder
cancer patients post-radical cystectomy: an XGBoost model study.
Transl Cancer Res. 2025;14:1902-1914. PubMed Abstract available
ZHU J, Zheng Z, Yin Z, Ding L, et al MiR-146b overexpression promotes bladder cancer cell growth via the
SMAD4/C-MYC/Cyclin D1 axis.
Front Oncol. 2025;15:1565638. PubMed Abstract available
SIREGAR GP, Parwati I, Tjahjodjati T, Safriadi F, et al Molecular Dynamic Stability Study of VEGF Inhibitor in Patients with Bladder
Cancer.
Acta Inform Med. 2025;33:50-53. PubMed Abstract available
KIKUCHI K, Ota I, Segawa T, Ieko Y, et al Survival outcomes and prognostic factors in bladder cancer treated with
radiotherapy.
J Radiat Res. 2025 Apr 14:rraf018. doi: 10.1093. PubMed Abstract available
ZHANG Y, Li Z, Zhao L, Yang Y, et al The therapeutic potential of brazilin in bladder cancer: inhibition of DNA
topoisomerase I and tumor growth suppression.
Naunyn Schmiedebergs Arch Pharmacol. 2025. PubMed Abstract available
REN W, Zhu Y Causal Associations Between the Presence of Prostate Cancer or Testosterone
Levels and Bladder Cancer Risk: A Mendelian Randomization Study.
Clin Genitourin Cancer. 2025;23:102334. PubMed Abstract available
YANG X, Yang R, Liu X, Chen Z, et al Recent Advances in Artificial Intelligence for Precision Diagnosis and Treatment
of Bladder Cancer: A Review.
Ann Surg Oncol. 2025 Apr 12. doi: 10.1245/s10434-025-17228. PubMed Abstract available
ISEMOTO K, Waseda Y, Fujiwara M, Kimura K, et al Predictive Potential of Contrast-Enhanced MRI-Based Delta-Radiomics for
Chemoradiation Responsiveness in Muscle-Invasive Bladder Cancer.
Diagnostics (Basel). 2025;15:801. PubMed Abstract available
OTO J, Herranz R, Plana E, Perez-Ardavin J, et al Validation of a microRNA profile in urine liquid biopsy with diagnostic and
stratification value for bladder cancer classification, available through the
open app BladdermiRaCan.
Exp Hematol Oncol. 2025;14:58. PubMed Abstract available
HERMANS T, Schevenels G, Motmans S, De Sutter T, et al Stapled vs. manually sutured bowel anastomosis in robot-assisted radical
cystectomy: a single-center retrospective analysis.
BMC Urol. 2025;25:85. PubMed Abstract available
ZHU Q, Zhang G, Cao M, Huang H, et al Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder
cancer.
Nat Immunol. 2025 Apr 11. doi: 10.1038/s41590-025-02126. PubMed Abstract available
EBNER B, Eismann L, Hermans J, Kidess M, et al Prognostic impact of combined loss of RB1, p53 and p21 in muscle-invasive bladder
cancer.
Pathol Res Pract. 2025;270:155960. PubMed Abstract available
LI YJ, Chen YH, Wang JW, Wu HH, et al Suppression of cisplatin induced ATF3 expression and apoptosis by BK polyomavirus
and its encoded microRNA in bladder cancer cells.
Biomed Pharmacother. 2025;186:118032. PubMed Abstract available
CHEN J, Yang X, Jia S, Zhang S, et al Identification and characterization of tubulin as Ga(III)-binding protein in T24
cells.
J Pharm Biomed Anal. 2025;261:116842. PubMed Abstract available
CARLSEN B, Klingen TA, Andreassen BK, Beisland C, et al Detection and agreement of blood- and lymph vessel invasion assessed by
immunohistochemistry in matched TURBT and radical cystectomy specimens.
Pathol Res Pract. 2025;269:155917. PubMed Abstract available
ZHU S, Li J, Sun H, Liang J, et al A biotin guided Pt(IV) amphiphilic prodrug synergized with CDK4/6 inhibition for
enhanced tumor targeted therapy.
Nanoscale. 2025;17:9907-9913. PubMed Abstract available
HOLLER SD, Smith SM Practical use of nadofaragene firadenovec-vncg for pharmacists.
J Oncol Pharm Pract. 2025;31:488-494. PubMed Abstract available
XU Z, Wang Q, Li B, Hao X, et al An updated systematic review, meta-analysis, and trial sequential analysis of the
efficacy and safety of en bloc transurethral resection vs. conventional
transurethral resection for nonmuscle-invasive bladder tumor.
Int J Surg. 2025;111:3061-3077. PubMed Abstract available
ROCHNER P, Rothlauf F Evaluating robustly standardized explainable anomaly detection of implausible
variables in cancer data.
J Am Med Inform Assoc. 2025;32:724-735. PubMed Abstract available
KATTAN J, Kattan C, Aoun F, Nemr E, et al The practical roadmap for peri-cystectomy approaches in muscle-invasive bladder
cancer.
Front Oncol. 2025;15:1543837. PubMed Abstract available
TSUKAHARA S, Shiota M, Matsumoto T, Takamatsu D, et al Monitoring circulating tumor DNA by recurrent hotspot mutations in bladder
cancer.
BJC Rep. 2025;3:26. PubMed Abstract available
ZHANG JH, Joyce DD, Shan Y, Fadel A, et al National complication and cost burden of transurethral resection of bladder tumor
for bladder cancer.
Urol Oncol. 2025 Apr 23:S1078-1439(25)00085. PubMed Abstract available
FREITAS R, Peixoto A, Santos LL, Ferreira JA, et al Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical
barriers.
Biochim Biophys Acta Rev Cancer. 2025 Apr 22:189327. PubMed Abstract available
ZAFFRAN I, Zoabi Y, Gaur P, Alekberli FR, et al Eosinophils but not mast cells exert anti-tumorigenic activity, without being
predictive markers of the long-term response to Bacillus Calmette-Guerin (BCG)
therapy in patients with bladder carcinoma.
Inflamm Res. 2025;74:68. PubMed Abstract available
POLATI D, Neerati P Synergistic effects of curcumin and piperine in cocrystal form: a breakthrough in
bladder cancer therapy.
J Biomater Sci Polym Ed. 2025 Apr 24:1-28. doi: 10.1080/09205063.2025.2491606. PubMed Abstract available
LV Z, Zhao S, Wu H LIMA1 inhibits cisplatin resistance and malignant biological behavior of bladder
cancer cells by suppressing the Wnt/beta-catenin pathway.
BMC Med Genomics. 2025;18:78. PubMed Abstract available
CHEN K, Chen J, Cong Y, He Q, et al TTK promotes mitophagy by regulating ULK1 phosphorylation and pre-mRNA splicing
to inhibit mitochondrial apoptosis in bladder cancer.
Cell Death Differ. 2025 Apr 23. doi: 10.1038/s41418-025-01492. PubMed Abstract available
LIM BJH, Fong KY, Lu T, Ong J, et al BCG response and oncological outcomes in high risk nonmuscle invasive bladder
cancer following previously treated upper tract urothelial carcinoma: A
propensity-matched analysis.
Urol Oncol. 2025 Apr 22:S1078-1439(25)00126. PubMed Abstract available
JING X, Deng Y ADCYAP1 as a pan-solid cancer biomarker: predictor of immunotherapy efficacy in
bladder cancer and prognostic potential across solid tumors.
Discov Oncol. 2025;16:593. PubMed Abstract available
MAN X, Dong C, Song X, Dong A, et al Intense FDG Activity of Renal Granuloma Following Intravesical Bacillus
Calmette-Guerin Therapy for Bladder Cancer Mimicking Malignancy.
Clin Nucl Med. 2025 Apr 23. doi: 10.1097/RLU.0000000000005810. PubMed Abstract available
QIU X, Wang F, Gao X, Zhang H, et al Detection of hyaluronidase in urine using hyaluronic acid-coated silver
nanoparticles-based surface-enhanced Raman spectroscopy for the diagnosis of
bladder cancer.
Talanta. 2025;294:128139. PubMed Abstract available
JIN J, Wang W, Zhao K, Xu G, et al The genetic associations of lipidome on bladder cancer: a Mendelian randomization
study.
Discov Oncol. 2025;16:586. PubMed Abstract available
CHEN Y, Xie H, Zou Y, Lai X, et al Retraction: Tetracycline-controllable artificial microRNA-HOTAIR + EZH2
suppressed the progression of bladder cancer cells.
Mol Omics. 2025 Apr 22. doi: 10.1039/d5mo90007. PubMed Abstract available
DAI H, Yu Z, Zhao Y, Jiang K, et al Integrating machine learning models with multi-omics analysis to decipher the
prognostic significance of mitotic catastrophe heterogeneity in bladder cancer.
Biol Direct. 2025;20:56. PubMed Abstract available
DENG D, Li J, Luo J, Liang H, et al Transurethral resection of a giant bladder leiomyoma.
BMC Urol. 2025;25:97. PubMed Abstract available
LUO J, Guo L, Fan J, Chen L, et al A review and meta-analysis: comparing the efficacy of robot-assisted and open
radical cystectomy in elderly bladder cancer patients.
J Robot Surg. 2025;19:168. PubMed Abstract available
SABEEL Z, Wang J, Dong J, Liu Y, et al The duality of GSK-3beta in urinary bladder cancer: Tumor suppressor and promoter
roles through multiple signaling pathways.
Biochim Biophys Acta Rev Cancer. 2025;1880:189324. PubMed Abstract available
SUBIELA JD, Guerrero-Ramos F, Rodriguez-Faba O, Aumatell J, et al New insights and emerging approaches in bladder-sparing treatment for
muscle-invasive bladder cancer.
Actas Urol Esp (Engl Ed). 2025 Apr 19:501758. doi: 10.1016/j.acuroe.2025.501758. PubMed Abstract available
NG TSC, Liu M, Robertson M, Konik A, et al A pilot study of [(18)F]F-fluciclovine positron emission tomography/computed
tomography for staging muscle invasive bladder cancer preceding radical
cystectomy.
Eur J Nucl Med Mol Imaging. 2025 Apr 21. doi: 10.1007/s00259-025-07287. PubMed Abstract available
ANNAKIB S, Di Meglio E, Dibert-Bekoy Y, Chevallier T, et al Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic
Bladder Cancer Patients.
Cancer Med. 2025;14:e70896. PubMed Abstract available
AMAN H, Hamza M, Ramzan A, Saqib M, et al Standard Versus Extended Pelvic Lymphadenectomy in Patients With Bladder Cancer:
A Systematic Review and Meta-analysis.
Am J Clin Oncol. 2025 Apr 21. doi: 10.1097/COC.0000000000001206. PubMed Abstract available
KAMIKAWA H, Matsukawa Y, Nishii H, Naito Y, et al A case of severe immune-related adverse events, myocarditis with myositis, and
myasthenia gravis overlap syndrome following adjuvant nivolumab administration
for muscle-invasive bladder cancer.
Nagoya J Med Sci. 2025;87:156-162. PubMed Abstract available
YIN ZX, Qiu Y, Xu C, Pei C, et al Comprehensive analysis of angiogenesis and stemness-related genes in chemotherapy
and immunotherapy of bladder cancer.
Biomol Biomed. 2025 Apr 18. doi: 10.17305/bb.2025.12046. PubMed Abstract available
BABA T, Hamada S, Sakiyama H, Kiyuna S, et al Simultaneous Laparoscopic and Thoracoscopic Biopsy via a Single Skin Incision
Using a Port-Sharing Procedure in Infantile Neuroblastoma: A Case Report.
Asian J Endosc Surg. 2025;18:e70064. PubMed Abstract available
AYDIN U, Cetin S, Koparal MY, Coskun C, et al Is the presence of lymphovascular invasion associated with recurrence and
progression in bladder cancer patients that have received adequate BCG therapy?
Actas Urol Esp (Engl Ed). 2025 Apr 18:501785. doi: 10.1016/j.acuroe.2025.501785. PubMed Abstract available
WANG JM, Zhang FH, Xie HY, Liu ZX, et al KIF26B promotes bladder cancer progression via activating Wnt/beta-catenin signaling
in a TRAF2-dependent pathway.
Cell Rep. 2025;44:115595. PubMed Abstract available
MOREIRA IB, Buettner FFR Glycosphingolipids as emerging attack points in bladder cancer.
Discov Oncol. 2025;16:569. PubMed Abstract available
RETRACTION: Comparative Analysis of Wound Healing Techniques in Postoperative
Bladder Cancer Patients.
Int Wound J. 2025;22:e70541. PubMed Abstract available
YE Z, Li Y, Sun Y, He C, et al Leveraging Deep Learning in Real-Time Intelligent Bladder Tumor Detection During
Cystoscopy: A Diagnostic Study.
Ann Surg Oncol. 2025;32:3220-3226. PubMed Abstract available
SANGOI AR, Shahabi A, Hirsch MS, Kao CS, et al Urothelial carcinoma in situ with "early papillary formation" vs "lateral
spread/shoulder lesion" of prior high-grade noninvasive papillary urothelial
carcinoma: A survey of pathologist and urologist interpretations.
Am J Clin Pathol. 2025;163:629-640. PubMed Abstract available
CASE KB, Martini DJ, Dababneh MN, Bidot S, et al Trop-2 and Ephrin B2 expression in urothelial carcinoma with divergent
differentiation and aggressive urothelial carcinoma subtypes.
Am J Clin Pathol. 2025;163:618-628. PubMed Abstract available
ADYPAGAVANE A, Lebacle C, Peyrottes A, Irani J, et al BCG MEDAC(R) for the treatment of non-muscle invasive bladder tumors: Adverse
events and predictive factors for tolerance.
Fr J Urol. 2025;35:102843. PubMed Abstract available
MUSANGILE FY, Matsuzaki I, Iwamoto R, Sagan K, et al Comparative analysis of non-coding and coding DNA mutations in flat urothelial
lesions: biological implications and insights.
Virchows Arch. 2025;486:729-737. PubMed Abstract available
OZYIGIT G, Kahvecioglu A, Cengiz M, Yedekci FY, et al The effect of incidental dose to pelvic nodes in bladder-only irradiation in the
era of IMRT: a dosimetric study.
Strahlenther Onkol. 2025;201:501-506. PubMed Abstract available
BOSVELD J, Nguyen TQ, Boormans JL, Witjes JA, et al The impact of positive surgical margins after cystectomy on oncological outcomes:
a nationwide study.
BJU Int. 2025;135:766-774. PubMed Abstract available
NUIJENS ST, van Hoogstraten LMC, Terpstra NB, Beeren I, et al The impact of treatment for muscle-invasive bladder cancer on health-related
quality of life.
BJU Int. 2025 Apr 16. doi: 10.1111/bju.16736. PubMed Abstract available
BRYAN RT, Patel P, Kennish SJ, Catto JWF, et al Improving the pathway to correct treatment for patients with muscle-invasive
bladder cancer: exploring the myths around the BladderPath trial.
BJU Int. 2025 Apr 14. doi: 10.1111/bju.16728. PubMed
RUDER S, Martinez J, Palmer J, Arham AB, et al Antibody-drug conjugates in urothelial carcinoma: current status and future.
Curr Opin Urol. 2025;35:292-300. PubMed Abstract available
DUWE G, Mercier D, Kauth V, Moench K, et al Development of an artificial intelligence-generated, explainable treatment
recommendation system for urothelial carcinoma and renal cell carcinoma to
support multidisciplinary cancer conferences.
Eur J Cancer. 2025;220:115367. PubMed Abstract available
GUPTA S, Hensley PJ, Li R, Choudhury A, et al Bladder Preservation Strategies in Muscle-invasive Bladder Cancer:
Recommendations from the International Bladder Cancer Group.
Eur Urol. 2025 Apr 22:S0302-2838(25)00189-7. doi: 10.1016/j.eururo.2025. PubMed Abstract available
GHODOUSSIPOUR S, Bivalacqua T, Bryan RT, Li R, et al A Systematic Review of Novel Intravesical Approaches for the Treatment of
Patients with Non-muscle-invasive Bladder Cancer.
Eur Urol. 2025 Apr 18:S0302-2838(25)00123-X. doi: 10.1016/j.eururo.2025. PubMed Abstract available
NAITO R, Izumi K, Takimoto A, Nakagawa R, et al Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival
of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?
Int J Urol. 2025 Apr 11. doi: 10.1111/iju.70064. PubMed Abstract available
SIMHAL RK, McPartland C, Wang KR, Buck M, et al Bowel regimens before radical cystectomy: An analysis of a modern cohort.
Int J Urol. 2025;32:402-408. PubMed Abstract available
AKPINAR C, Suer E, Akdogan B, Izol V, et al The effect of neoadjuvant chemotherapy on survival outcomes in patients with
variant histologies who underwent radical cystectomy with precystectomy
diagnostic accuracy: A multicenter study of the Turkish Urooncology Association.
Int J Urol. 2025;32:508-515. PubMed Abstract available
PLAGE H, Furlano K, Hofbauer S, Rossner F, et al PLAP expression is linked to invasive tumor growth in urothelial carcinoma of the
bladder.
Int Urol Nephrol. 2025;57:1381-1388. PubMed Abstract available
WONG TR, Sun C, Ledesma B, Isali I, et al The role of angiogenin in bladder cancer: where are we in 2025?
Int Urol Nephrol. 2025 Apr 22. doi: 10.1007/s11255-025-04517. PubMed Abstract available
BRYAN RT, Liu W, Pirrie SJ, Amir R, et al Errata: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral
Resection for Staging New Bladder Cancers: Results From the Prospective
BladderPath Trial.
J Clin Oncol. 2025 Apr 23:JCO2500779. doi: 10.1200/JCO-25-00779. PubMed
LOTAN Y, Li R, Chang SS AI Biomarkers Predict Poor Efficacy of BCG Rechallenge in Previously BCG-Treated
Non-muscle Invasive Bladder Cancer.
J Urol. 2025 Apr 16:101097JU0000000000004541. doi: 10.1097/JU.0000000000004541. PubMed
ZHONG Y, Wei J, Jiang R Letter: Hybrid 3-Tier Bladder Cancer Grade: The Mutually Beneficial Marriage of 2
Grading Systems.
J Urol. 2025 Apr 15:101097JU0000000000004555. doi: 10.1097/JU.0000000000004555. PubMed
WU CH, Yuen KL, Molony RD, Silvers CR, et al Protein disulfide isomerase-enriched extracellular vesicles from bladder cancer
cells support tumor survival and malignant transformation in the bladder.
Oncogene. 2025 Apr 11. doi: 10.1038/s41388-025-03380. PubMed Abstract available
HU H, Zhan X, Xiong Y, Yuan R, et al Non-classic deubiquitinase USP13 inhibits bladder cancer metastasis through
destabilizing cytoplasmic KDM3A.
Oncogene. 2025 Apr 19. doi: 10.1038/s41388-025-03410. PubMed Abstract available
ELSAEED K, Moustafa H, Abdelghani S, ElAwady H, et al Anti-Reflux Ureteroileal Anastomosis for Orthotopic Ileal Neobladder Using
Wallace Technique in a Single Trough.
Urol Int. 2025;109:182-188. PubMed Abstract available
JOYCE DD Editorial Comment on "Real-World Economic Burden and Healthcare Resource
Utilization of Radical Cystectomy and Trimodal Therapy for Bladder Cancer in the
United States".
Urology. 2025 Apr 7:S0090-4295(25)00317-6. doi: 10.1016/j.urology.2025. PubMed
SAITO K, Nakayama A Editorial comments on Survival outcomes and temporal trends of non-surgical
management versus radical cystectomy in non-organ-confined urothelial bladder
cancer.
Urology. 2025 Apr 4:S0090-4295(25)00319-X. doi: 10.1016/j.urology.2025. PubMed
ACOSTA AM, Saad M, Chaux A, Gordetsky JB, et al Differential Outcomes in Bladder Cancer After Neoadjuvant Chemotherapy: An
International Multi-Institutional Study Comparing Isolated Nodal Disease versus
Persistent Muscle-Invasive Disease.
Urology. 2025 Apr 16:S0090-4295(25)00345-0. doi: 10.1016/j.urology.2025. PubMed Abstract available
LONGONI M, Penaranda NR, Marmiroli A, Falkenbach F, et al Reply to Editorial Comment on "Survival Outcomes And Temporal Trends Of
Non-Surgical Management Versus Radical Cystectomy In Non-Organ-Confined
Urothelial Bladder Cancer".
Urology. 2025 Apr 15:S0090-4295(25)00341-3. doi: 10.1016/j.urology.2025. PubMed
QIU H, Deng X, Zha J, Wu L, et al Machine learning-based characterization of stemness features and construction of
a stemness subtype classifier for bladder cancer.
BMC Cancer. 2025;25:717. PubMed Abstract available
LI Z, Su M, Li Q, Zheng X, et al The role of CDK8 gene polymorphisms in bladder cancer susceptibility and
prognosis: a study in the Chinese Han population.
BMC Cancer. 2025;25:714. PubMed Abstract available
PLAGE H, Ahlburg V, Hofbauer S, Furlano K, et al Loss of chromosome Y is unrelated to the composition of the tumor
microenvironment and patient prognosis in muscle-invasive urothelial bladder
cancers.
BMC Cancer. 2025;25:677. PubMed Abstract available
